<DOC>
	<DOCNO>NCT02700464</DOCNO>
	<brief_summary>Clinical trial determine efficacy ( sensitivity specificity ) Bladder EpiCheck test compare gold standard cystoscopy pathology patient monitor recurrence bladder cancer .</brief_summary>
	<brief_title>The Efficacy Bladder EpiCheck Detection Recurrent Urothelial Cell Carcinoma</brief_title>
	<detailed_description>The Bladder EpiCheck test vitro diagnostic device detection DNA methylation pattern urine associate bladder cancer . It intend use noninvasive method monitoring tumor recurrence conjunction cystoscopy inpatient previously diagnose bladder cancer This , multicenter , prospective , blind study evaluate efficacy ( sensitivity specificity ) novel methylation test detection recurrent Urothelial Cell Carcinoma patient history bladder cancer undergo surveillance .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Any male female patient diagnose incident recurrent Urothelial Cell Carcinoma undergo surveillance 3 month interval . Has urothelial cell carcinoma tumor resect within past 12 month Has plan cystoscopic surveillance ( adjuvant intravesical therapy allow ) Able provide legally effective informed consent Able produce 45mL urine Planning undergo radical cystectomy chemotherapyradiation Urothelial Cell Carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>